About Be4
Be4 is a Healthcare company based in Bedford (United Kingdom) founded in 2009, and was acquired by UCB in June 2017. Drug discovery solutions are offered by Beryllium through specialized services. Be4 has raised $11.5 million across 6 funding rounds from investors including UCB and HHS. The company has 55 employees. Be4 has completed 1 acquisition, including Emerald BioSystems. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Structural Biology. Its legal entity is BERYLLIUM LTD.
Company details
Beryllium was founded in 2009 and operates from Bedford, United Kingdom, as a contract research organization in the biotechnology sector. Collaborative partnerships are formed with companies to address challenges in drug discovery. Services provided include structure determination using NMR and X-ray crystallography, gene-to-protein production, antibody-antigen characterization, functional biology assays, fragment screening, target gallery development, and membrane protein work.
Funding Insights of Be4
Be4 has successfully raised a total of $11.5M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $7.5 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.5M
- Total Rounds 6
- Last Round Series A — $7.5M
- First Round $7.54M
(Jul 2008)
- Investors Count 2
All 6 funding rounds of Be4 with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Be4
Be4 has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include UCB and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Be4
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Be4
Be4 has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Emerald BioSystems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Laboratory automation, bioinformatics software, reagent kits and plastic-ware products | emeraldbiosystems.com | Bainbridge Island, United States | 1998 | Nov 2009 | •••• |
Complete acquisition details for Be4
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Be4
5 dated milestones of Be4 across 9 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $7.5M.
- Founded Be4 is founded.
- Acquisition Acquires Emerald BioSystems.
- Funding Latest funding round, Series A, of $7.5M.
- Exit Acquired by UCB.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Be4 (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Be4
Be4 was founded in 2009.
Be4 is headquartered in Bedford, United Kingdom. It is registered at Bedford, Bedfordshire, United Kingdom.
Be4 is a funded company, having raised a total of $11.5M across 6 funding rounds to date. The company's 1st funding round was a Grant of $7.54M, raised on Jul 2008.
Be4 has 55 employees.
Beryllium was founded in 2009 and operates from Bedford, United Kingdom, as a contract research organization in the biotechnology sector. Collaborative partnerships are formed with companies to address challenges in drug discovery. Services provided include structure determination using NMR and X-ray crystallography, gene-to-protein production, antibody-antigen characterization, functional biology assays, fragment screening, target gallery development, and membrane protein work.
Be4 has made 1 acquisition, including Emerald BioSystems.
Be4 operates through Beryllium Ltd.
Yes. Be4 was acquired by UCB in June 2017.